Nerve Sheath Tumors of the Spine

Nerve sheath tumours make up 25-30% of all intradural spinal tumours. They arise either from Schwann cells, as schwannomas (70-80%), or from nerve sheath fibroblasts, as neurofibromas (20-30%). Both are benign, and both present with radicular pain and progressive myelopathy.

The distinction that drives surgery. A schwannoma is typically solitary, encapsulated and eccentric to its nerve root, and is amenable to complete resection with the nerve preserved. A neurofibroma is more infiltrative, involves the nerve fascicles, often requires sacrifice of the nerve, and is associated with neurofibromatosis type 1 (NF1).

Recognition. Radicular pain is the initial symptom in 80-90% of cases. MRI shows an intradural extramedullary mass that enhances with contrast, the CSF protein is raised, and 15-30% have a dumbbell configuration, with intraspinal and paraspinal components.

The diagnostic pathway.

1. MRI of the whole spine with gadolinium, the gold standard
2. Screening for neurofibromatosis: café-au-lait spots and family history
3. CT for the bony anatomy where there is dumbbell extension
4. Pre-operative neurophysiology if a motor root is involved

Two numbers to quote separately. A schwannoma is removed completely in about 95%, but that is not the same as nerve preservation, which this page puts at 85-90%. The tumour comes out completely in 19 of 20; the root is kept intact in roughly 9 of 10.

The nerve root. The dorsal (sensory) root enters the posterolateral cord and the ventral (motor) root leaves the anterolateral cord; the two fuse in the foramen to form the mixed spinal nerve. The dorsal root ganglion holds the sensory cell bodies and is a common site of origin for schwannomas.

Where the Schwann cells are. Schwann cells myelinate peripheral nerves and are present on both the dorsal and the ventral roots distal to the root entry and exit zones. Most schwannomas (90%) arise from dorsal sensory roots. Motor root schwannomas are rare (10%) but clinically significant.

Compartments. Schwannomas are described by where they sit relative to the dural sac and the foramen:

• Intradural, within the dural sac: the most common (65%)
• Foraminal, within the neural foramen: 20%
• Dumbbell, both intradural and foraminal or paraspinal: 15%
• Paraspinal, entirely extraforaminal: rare (5%)

Which roots can be sacrificed. Knowing this guides the choice between complete resection and nerve preservation. Sensory (dorsal) roots are generally sacrificable with minimal morbidity, at the cost of dermatomal numbness. The limb roots are not: losing one of C5-T1 causes significant upper limb weakness, and L2-S1 are essential for ambulation.

Unilateral thoracic root sacrifice causes numbness only, but bilateral sacrifice can cause truncal instability.

Pathology. The table sets the three tumours side by side.

View larger

Malignant peripheral nerve sheath tumour (MPNST). MPNST is rare, under 5% of nerve sheath tumours, and presents with rapid growth, pain and neurological deficit. The prognosis is poor even with aggressive treatment, and wide en bloc resection is required. The lifetime risk is markedly increased in NF1, so a rapidly enlarging or painful nerve-sheath mass warrants urgent biopsy.

View larger

Why the pain is radicular. Compression of and traction on the nerve root, together with inflammation and chemical mediators, produce the pain. It is often nocturnal because the recumbent position increases intraspinal pressure.

Myelopathy. Progressive compression of the cord by a ventral or lateral tumour, and vascular compromise of the cord, produce myelopathy. It is a late manifestation, and the tumour is often large by then.

Natural history. Schwannomas grow slowly, 1-2 mm per year, and may remain asymptomatic for years. Neurofibromas grow variably, faster in NF1. Malignant transformation is rare in schwannomas (under 1%) and higher in NF1 neurofibromas (5-10%).

Symptoms progress through three stages.

Early: radicular pain. Unilateral dermatomal pain is present in 80-90% of patients. It is lancinating or burning, worse with movement, Valsalva, coughing, bending and recumbency, and partly relieved by particular positions. It may precede imaging findings by months to years.

Intermediate: root deficit. Motor and sensory deficits appear: dermatomal paraesthesia and numbness, progressive weakness in a myotomal distribution, atrophy of the affected muscles, reflex asymmetry or loss, and gait disturbance if a lower limb root is involved.

Late: myelopathy. Bilateral weakness below the tumour level, spasticity and hyperreflexia, a sensory level, and bladder and bowel dysfunction. This indicates significant cord compression requiring urgent surgery.

Inspection looks for the stigmata of NF1: café-au-lait spots, axillary or inguinal freckling, subcutaneous neurofibromas, Lisch nodules (iris hamartomas), and scoliosis (the NF1-associated dystrophic curve).

Motor and sensory examination. A root lesion gives myotomal weakness, muscle atrophy from chronic denervation, lower motor neuron fasciculations and dermatomal loss to pinprick and light touch. Cord compression adds pyramidal signs (hyperreflexia, spasticity, Babinski), posterior column dysfunction (vibration and proprioception) and a sensory level.

Special tests.

• Straight leg raise: positive with lumbar or sacral root involvement
• Spurling test: positive with cervical root compression
• Hoffmann and Babinski signs: present with myelopathy

Neurofibromatosis Screening

Features that are not criteria. Learning disability and attention deficit are associated with NF1, as is an increased risk of malignancy: MPNST, phaeochromocytoma, breast cancer, and optic pathway and other gliomas beyond the optic nerve.

NF1 in the spine. Expect multiple nerve sheath tumours (schwannomas and neurofibromas), paraspinal plexiform neurofibromas, dystrophic scoliosis with a short segment and severe angulation, and dural ectasia.

MRI

MRI is the gold standard. The protocol:

• Whole-spine sagittal and axial sequences
• T1-weighted, before and after gadolinium
• T2-weighted for cord signal
• STIR for oedema and bone involvement
• Thin (3 mm) cuts through the tumour

Schwannoma. An ovoid or round mass with well-defined margins, iso- to hypointense to cord on T1 and hyperintense on T2, with hypointense areas where there is fibrosis. Small tumours enhance intensely and homogeneously; large tumours with cystic degeneration enhance heterogeneously. A crescent of CSF around the tumour, the CSF cap, marks it as extramedullary, and the target sign (central low T2 signal with peripheral high signal) is specific but uncommon.

Neurofibroma. Often foraminal or paraspinal, it is a fusiform enlargement of the nerve, isointense on T1, very hyperintense on T2 from its myxoid matrix, and enhances heterogeneously. The target sign is more common than in schwannoma, and the tumours are often multiple in NF1.

View larger

View larger

Dumbbell tumours. The intraspinal component is an intradural extramedullary mass, the foraminal component widens the neural foramen (best seen on axial CT), and the paraspinal component is a soft-tissue mass lateral to the spine. The tumour takes an hourglass shape at the foramen and may erode bone and destroy the facet.

View larger

View larger

View larger

View larger

CT

CT is for the bone, particularly in dumbbell tumours. It shows the widened neural foramen, facet erosion or destruction, vertebral body scalloping and the paraspinal soft-tissue mass, and it is used to plan foraminal enlargement. Calcification is rare; if present, consider meningioma.

Differential Diagnosis

Series disagree on level. The two schwannoma series in the Evidence Base do not follow the table's cervical-first order: Conti's 179 tumours were lumbosacral (87), then thoracic (59), then cervical (33), and lumbar tumours were the commonest in Jeon's 40.

Laboratory Tests, CSF and Neurophysiology

Pre-operative work-up. Full blood count, renal and liver function, a coagulation profile, group and screen (blood products are rarely needed), ECG and anaesthetic assessment.

CSF analysis is rarely needed. The protein is raised in 60-80% of cases, with a normal glucose and cell count.

Froin syndrome. Described by Georges Froin in 1903, and also called the loculation or Nonne-Froin syndrome, it is the set of CSF changes found at lumbar puncture below a lesion that completely obstructs the spinal subarachnoid space. It is the lumbar-puncture fingerprint of a nerve sheath tumour that has obstructed that space, and remains a favourite viva and MCQ item. The classic triad:

• Xanthochromia: yellow discoloration of the CSF produced by its very high protein content, and at times by prior microhaemorrhage
• Markedly elevated protein (hyperproteinorrachia), often over 1000 mg/dL, with a normal cell count, a dissociation termed albuminocytological dissociation
• Spontaneous hypercoagulation: the fluid clots on standing because of its high fibrinogen and protein load

The mechanism. A large intradural extramedullary tumour (schwannoma, neurofibroma or meningioma) fills the canal and isolates the CSF caudal to it. The stagnant fluid below the block equilibrates with plasma proteins across leaky tumour vessels while normal CSF turnover ceases, so protein accumulates dramatically. Because the sample is drawn below the block, glucose and cell count are typically normal, which distinguishes Froin's picture from infective or malignant meningitis.

Recognise it, do not reproduce it. The block was historically demonstrated with the Queckenstedt test: manual jugular compression fails to raise lumbar CSF pressure when the subarachnoid space is obstructed. MRI has now replaced both the Queckenstedt test and diagnostic lumbar puncture. A Froin-type CSF picture should prompt urgent whole-spine gadolinium MRI rather than repeated taps, and lumbar puncture below a suspected complete block is best avoided because of the risk of neurological deterioration as fluid is withdrawn across the obstruction.

Neurophysiology. EMG and nerve conduction studies localise root involvement and record pre-operative motor and sensory baselines. Intraoperatively, SSEPs monitor the sensory roots and triggered EMG the motor roots.

Surgical Indications

Absolute indications. Operate for any of:

• Progressive neurological deficit
• Myelopathy (cord compression)
• Intractable radicular pain affecting quality of life
• Suspicion of malignancy (rapid growth, NF1 patient)

Relative indications.

• Asymptomatic tumour with radiological progression
• Large tumour, over 2 cm, even if minimally symptomatic
• Dumbbell tumour with foraminal widening
• Patient preference after discussion of the natural history

Observation. Small asymptomatic tumours (under 1 cm), elderly or medically unfit patients, and the multiple tumours of NF1, where the symptomatic lesions are prioritised, can be observed with serial MRI every 6-12 months to assess growth.

Standard Posterior Approach

A posterior laminectomy approach suits purely intradural tumours and those with a small foraminal component that does not need facetectomy, which is the majority of nerve sheath tumours.

Set-up. Prone on a radiolucent table, in Mayfield fixation for the cervical spine or padded prone for the thoracolumbar spine. Intraoperative neuromonitoring uses SSEP, with triggered EMG to identify motor roots, and fluoroscopy localises the exact tumour level.

Exposure. A midline incision over the affected levels and subperiosteal muscle dissection lead to a hemilaminectomy on the tumour side, preserving the contralateral lamina and facets; it may be extended to a laminectomy if the tumour crosses the midline. Preserve the facet capsule to prevent instability.

Dural opening. A midline durotomy with tacking sutures opens the intradural space for inspection under the microscope. Identify the tumour, usually posterolateral, and its relationship to the nerve root and cord.

Resecting a schwannoma.

1. Sharply incise the arachnoid over the tumour
2. Identify the nerve root of origin, usually dorsal
3. Coagulate the feeding vessels with bipolar
4. Dissect circumferentially around the capsule, preserving the fascicles splayed over its surface
5. Stimulate the root with triggered EMG to confirm motor versus sensory
6. Divide the root proximally and distally if it is sensory and non-essential; attempt nerve preservation if it is a motor root
7. Remove the tumour en bloc

Resecting a neurofibroma. The tumour is more infiltrative into the fascicles. Attempt intracapsular debulking first and assess root function with stimulation. On a motor root, accept subtotal resection to preserve function; on a sensory root (C1-C4, T2-T12), the nerve may be sacrificed for gross total resection.

Closure. Meticulous haemostasis, a watertight dural closure with a running 4-0 suture and dural sealant, then muscle and fascia in layers and a subcuticular skin closure.

View larger

Dumbbell Tumours

Small to moderate (extraforaminal component under 3 cm). A posterior approach with unilateral laminectomy plus medial facetectomy (under 50%), widening the foramen with a high-speed drill. Remove the intraspinal component first, then deliver the extraforaminal component through the foramen. Pedicle screw fixation may be required if more than 50% of the facet is removed.

Large (extraforaminal component over 3 cm). Consider a staged or combined approach:

• Posterior approach with complete facetectomy and fusion
• Anterior or lateral retropleural or retroperitoneal approach for the paraspinal component, then posterior for the intraspinal component
• Combined single-stage anterior-posterior approach

Cervical. A large paraspinal component is approached from the front, through the anterolateral (Henry) approach to the cervical spine. Mobilise the carotid sheath and oesophagus, identify and protect the vertebral artery, and resect the paraspinal component; the foramen may be accessed from anteriorly. The intradural component is removed through a staged posterior approach.

Thoracic. A transthoracic or thoracoscopic approach in the lateral decubitus position, through a rib resection or thoracoscopic ports, mobilises the lung and parietal pleura and gives excellent visualisation of the paraspinal tumour. A hemilaminectomy deals with the intradural component.

View larger

Lumbar. A retroperitoneal or transperitoneal approach gives anterior access to the psoas and paraspinal region. Mobilise the great vessels and ureter and resect the paraspinal component; a posterior laminectomy removes the intradural tumour.

View larger

View larger

View larger

Nerve Root Preservation

Planning. Review the MRI to determine the root of origin, predict from its location whether it is motor or sensory, and discuss with the patient the potential for root sacrifice and the deficit to expect.

Identifying the root. Stimulate the proximal root with triggered EMG. A low-threshold response (under 0.5 mA) indicates a motor root; a high threshold or no response indicates a sensory root. Stimulate the distal root after resection to confirm function.

Preserving it. A schwannoma displaces the nerve eccentrically and leaves the fascicles on its capsule, where sharp dissection along the capsule can preserve them. If the tumour arises from a motor root, attempt intracapsular debulking to preserve the root, and accept subtotal resection if nerve preservation is critical.

The sacrifice decision.

• Sensory roots (C1-C4, T2-T12, and S3-S5 on one side): safe to sacrifice for gross total resection
• Motor roots (C5-T1, L2-S2): attempt preservation
• A motor root that is completely non-functional (no EMG response, severe atrophy): sacrifice acceptable
• Bilateral motor root sacrifice: never acceptable

Complications

Expected deficits versus complications. Some deficits are the planned price of the operation: dermatomal numbness is expected after a sensory root is sacrificed and is usually well tolerated, and weakness or numbness after any root sacrifice depends on the root. Anticipate these, and distinguish them from complications that need intervention.

Wound infection in the largest series. Safaee's 221 nerve sheath tumours (Evidence Base) had a wound infection rate of 5%, above the figure in the table, and an overall complication rate of 32%, most often new or worsening sensory symptoms.

Spinal instability. The risk factors are bilateral facetectomy of more than 50%, multilevel laminectomy and pre-existing scoliosis. It presents with mechanical back pain and progressive deformity. Prevention is prophylactic fusion when facet resection is high-risk; management is posterior instrumented fusion if symptomatic.

Tumour recurrence.

• Schwannoma: under 5% after gross total resection, higher after subtotal resection
• Neurofibroma: 10-15%, higher in NF1
• MPNST: high recurrence even after gross total resection, with a poor prognosis

Surveillance MRI follows at 3 months, 1 year and then every 2 years for a schwannoma, and annually for a neurofibroma and in NF1.

Chronic pain. Persistent or new radicular pain affects 5-10% of patients and usually improves over months. The mechanisms are nerve injury, epidural scarring and arachnoiditis; management is multimodal analgesia, neuropathic pain medication and pain clinic referral.

Sacral nerve sheath tumours behave differently from those higher in the spine. The S2-S5 roots carry bladder, bowel and sexual function, and the roomy sacral canal lets a tumour grow silently.

Why they present late and large. The capacious sacral canal and pre-sacral space allow a schwannoma or neurofibroma to reach a very large ("giant") size before it produces symptoms. Presentation is therefore insidious, with vague low back or pelvic pain, a palpable pre-sacral or buttock mass, or bladder, bowel and sexual dysfunction, rather than a sharp radiculopathy.

Imaging. CT shows a well-marginated lytic lesion that scallops and expands the sacrum with a smooth sclerotic rim, while MRI defines the intracanal and pre-sacral extent. The principal alternatives to exclude are chordoma (midline, calcifies, destroys bone) and metastasis.

View larger

Approach selection.

• Posterior (trans-sacral) approach: suffices for tumours largely confined to the sacral canal and dorsal sacrum
• Combined anterior (trans-abdominal or retroperitoneal) plus posterior approach, sometimes staged: for large pre-sacral components; the anterior stage controls the middle sacral and internal iliac vessels and protects the rectum, ureters and lumbosacral plexus before the posterior sacral resection

View larger

Resection versus continence. Unlike an expendable thoracic sensory root, the sacral roots carry pelvic autonomic function, so gross total resection must be balanced against sphincter preservation. The working principles:

• Preserving both S2 roots and at least one S3 generally maintains useful bladder, bowel and sexual function
• Bilateral sacrifice of S2 and below typically produces a neurogenic bladder and bowel with sexual dysfunction
• Unilateral sacrifice of an entire S1-S5 side is usually tolerated if the contralateral roots are intact

Match the resection to the histology. For a benign schwannoma it is acceptable to leave tumour on a functioning sphincter root (planned subtotal resection) rather than render the patient incontinent, which makes the giant sacral schwannoma one of the few settings where subtotal resection is deliberately accepted. Aggressive en bloc excision is reserved for malignant lesions such as MPNST, where oncological margins dominate. As elsewhere, intraoperative EMG and root stimulation guide which roots can be safely divided.

Global Epidemiology

• Nerve sheath tumours account for roughly 25–30% of intradural extramedullary spinal tumours; schwannomas predominate (70–80%) over neurofibromas.
• Peak incidence is in the fourth to sixth decades with no strong sex predilection (unlike spinal meningioma, which is markedly female-predominant).
• Most are sporadic and solitary. Multiplicity should prompt evaluation for a tumour-predisposition syndrome — NF1, NF2, or schwannomatosis (including SMARCB1/LZTR1-related disease).
• MPNST is rare overall but its lifetime risk rises to roughly 8–13% in NF1, making new pain or rapid growth in an NF1 patient a red flag worldwide.

Diagnostic & Syndrome Criteria (Side by Side)

Society Guidance & Practice Variation

• No single dedicated society "guideline" governs sporadic spinal nerve sheath tumour surgery; practice is guided by WHO CNS tumour classification (5th edition, 2021) for pathology and grading, NIH/revised international diagnostic criteria for NF1, and the Manchester criteria for NF2.
• Surgical principles are broadly concordant across AANS/CNS (US), the British Association of Spine Surgeons / SBNS (UK), EANS (Europe) and EFORT teaching: gross total microsurgical resection with neural preservation for symptomatic or growing tumours, observation with interval MRI for small asymptomatic lesions.
• WHO/NF management is increasingly delivered through specialist neurofibromatosis multidisciplinary clinics in high-resource settings, with genetic counselling and whole-neuraxis surveillance imaging.

Registry & Surveillance Notes

• Unlike arthroplasty, there is no large international implant registry for these tumours; outcome data derive from single-centre and multi-institutional surgical series and from national NF natural-history cohorts.
• High-resource settings: routine MRI with gadolinium, intraoperative neuromonitoring, microsurgical and minimally invasive corridors, and access to SRS and MDT NF clinics.
• Limited-resource settings: later presentation (larger tumours, established myelopathy), reliance on CT or non-contrast MRI, fewer neuromonitoring resources, and a lower threshold for open laminectomy with fusion where minimally invasive instrumentation is unavailable. The core operative principle — safe maximal resection with neural preservation — remains universal.

Nerve sheath tumour surgery is mature, but several decisions remain genuinely contested and are favourite viva discussion points.

• Routine vs selective intraoperative neuromonitoring. Triggered EMG and SSEP/MEP undeniably aid root identification, and in the largest series monitoring tracked with higher gross-total resection rates (79% vs 66%). However, no randomised trial demonstrates that monitoring reduces permanent deficits, and complication rates were similar with and without it. Practice ranges from mandatory for every intradural case to selective use for motor-root lesions.
• Extent of resection of the parent root. Classic teaching is to preserve the root of origin, yet historical data show the parent root is frequently already non-functional and sacrifice of even C5–T1 or L3–S1 roots produces a detectable deficit in only about a quarter of cases. The modern compromise is intracapsular debulking with functional preservation when stimulation confirms a live motor root, and en bloc removal when it does not.
• Prophylactic fusion after facetectomy. There is no consensus threshold. Many surgeons fuse after greater than 50% unilateral facet resection or any bilateral facetectomy, but minimally invasive far-lateral corridors have removed giant dumbbell tumours with no instrumentation, challenging the assumption that wide bony exposure mandates fusion.
• Management of asymptomatic and NF-associated tumours. Whether to operate on small asymptomatic lesions, and how aggressively to treat the multiple tumours of NF1/NF2 and schwannomatosis, is individualised. Most centres observe small stable lesions and operate selectively on symptomatic or growing ones, reserving prophylactic surgery for radiological progression.
• Role of stereotactic radiosurgery (SRS). SRS is established for intracranial schwannomas but its role for spinal nerve sheath tumours is limited to poor surgical candidates, residual/recurrent disease, or multiple NF-related lesions; durable high-level evidence is lacking and surgery remains first-line for accessible symptomatic tumours.
• MPNST adjuvant therapy. The benefit of radiotherapy and chemotherapy is uncertain. Foundational data showed no clear survival benefit, while more recent practice favours adjuvant radiotherapy for local control after marginal margins; complete resection remains the only consistently prognostic intervention.

1. Seppälä MT, Haltia MJ, Sankila RJ, Jääskeläinen JE, Heiskanen O. Long-term outcome after removal of spinal schwannoma: a clinicopathological study of 187 cases. J Neurosurg. 1995;83(4):621-626. PMID 7674010.

2. Conti P, Pansini G, Mouchaty H, Capuano C, Conti R. Spinal neurinomas: retrospective analysis and long-term outcome of 179 consecutively operated cases and review of the literature. Surg Neurol. 2004;61(1):34-43. PMID 14706374.

3. Jeon JH, Hwang HS, Jeong JH, Park SH, Moon JG, Kim CH. Spinal schwannoma; analysis of 40 cases. J Korean Neurosurg Soc. 2008;43(3):135-138. PMID 19096620.

4. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006-2021. PMID 3082508.

5. Kim P, Ebersold MJ, Onofrio BM, Quast LM. Surgery of spinal nerve schwannoma. Risk of neurological deficit after resection of involved root. J Neurosurg. 1989;71(6):810-814. PMID 2585070.

6. Safaee MM, Lyon R, Barbaro NM, et al. Neurological outcomes and surgical complications in 221 spinal nerve sheath tumors. J Neurosurg Spine. 2016;26(1):103-111. PMID 27472744.

7. Poblete J, Martinez Anda JJ, Rebollar Mendoza AA, et al. Minimally invasive surgical technique for the management of giant dumbbell spinal schwannoma. J Neurol Surg A Cent Eur Neurosurg. 2023;84(3):219-226. PMID 34911086.

8. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. 5th ed. Lyon: IARC; 2021.

9. Klekamp J, Samii M. Surgery of Spinal Tumors. Berlin: Springer-Verlag; 2007.

Related pages: Schwannoma and Neurofibroma for the two lesions in full, including the histology and the peripheral (non-spinal) presentations; Malignant Peripheral Nerve Sheath Tumour for the transformation this page screens against; Neurofibromatosis for the syndromes and the 2021 revised criteria in detail, and for the dystrophic scoliosis that accompanies paraspinal plexiform disease; Intradural Extramedullary Tumours for the wider differential at that compartment and Metastatic Spine Disease for the commonest competing diagnosis; MRI Neurography for the imaging signs; and Cauda Equina Syndrome for the presentation a lumbosacral lesion can produce.